Mirati Therapeutics (MRTX) News Today → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free MRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative January 30, 2024 | marketbeat.comMirati Therapeutics (NASDAQ:MRTX) Earns Sell Rating from Analysts at StockNews.comStockNews.com started coverage on Mirati Therapeutics in a research note on Tuesday. They issued a "sell" rating for the company.January 25, 2024 | marketbeat.comAssenagon Asset Management S.A. Boosts Stock Holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX)Assenagon Asset Management S.A. boosted its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX - Free Report) by 125.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,825,678 shareJanuary 23, 2024 | marketbeat.comTrading was temporarily halted for "MRTX" at 07:01 PM with a stated reason of "News pending."January 18, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Benjamin Hickey Sells 1,597 SharesMirati Therapeutics, Inc. (NASDAQ:MRTX - Get Free Report) EVP Benjamin Hickey sold 1,597 shares of the firm's stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $59.02, for a total transaction of $94,254.94. Following the completion of the sale, the executive vice president now owns 117,028 shares of the company's stock, valued at $6,906,992.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.January 16, 2024 | marketbeat.comTD Asset Management Inc Grows Position in Mirati Therapeutics, Inc. (NASDAQ:MRTX)TD Asset Management Inc increased its holdings in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX - Free Report) by 195.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 213,218 shares of the biotecJanuary 12, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Sees Large Decline in Short InterestMirati Therapeutics, Inc. (NASDAQ:MRTX - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 4,390,000 shares, a drop of 40.7% from the December 15th total of 7,400,000 shares. Based on an average trading volume of 2,150,000 shares, the days-to-cover ratio is presently 2.0 days.January 10, 2024 | markets.businessinsider.comMirati Therapeutics Receives Marketing Authorization For KRAZATI From European CommissionJanuary 10, 2024 | finance.yahoo.comEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationJanuary 10, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Receives Average Recommendation of "Hold" from AnalystsMirati Therapeutics, Inc. (NASDAQ:MRTX - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a hold recommendation and three haJanuary 9, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Sells $123,142.80 in StockMirati Therapeutics, Inc. (NASDAQ:MRTX - Get Free Report) EVP Benjamin Hickey sold 2,090 shares of the business's stock in a transaction on Monday, January 8th. The stock was sold at an average price of $58.92, for a total value of $123,142.80. Following the completion of the sale, the executive vice president now directly owns 118,625 shares in the company, valued at approximately $6,989,385. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.January 5, 2024 | marketbeat.comInsider Selling: Mirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Sells 1,531 Shares of StockMirati Therapeutics, Inc. (NASDAQ:MRTX - Get Free Report) EVP Jamie Christensen sold 1,531 shares of Mirati Therapeutics stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $58.81, for a total transaction of $90,038.11. Following the completion of the sale, the executive vice president now owns 157,135 shares in the company, valued at approximately $9,241,109.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.January 5, 2024 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Stock Position Reduced by Handelsbanken Fonder ABHandelsbanken Fonder AB trimmed its holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX - Free Report) by 84.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,900 shares of the biotechnology company's stDecember 28, 2023 | marketbeat.comSG Americas Securities LLC Buys 25,335 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX)SG Americas Securities LLC boosted its stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX - Free Report) by 104.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,578 shares of the biotechnology company's stockDecember 25, 2023 | seekingalpha.comEvaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers AcquisitionDecember 22, 2023 | reuters.comBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnDecember 22, 2023 | msn.comKaruna Therapeutics soars after $14 billion takeover by Bristol MyersDecember 20, 2023 | msn.comCitigroup Downgrades Mirati Therapeutics (MRTX)December 20, 2023 | finance.yahoo.comMirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 SharesDecember 20, 2023 | marketbeat.comMirati Therapeutics (NASDAQ:MRTX) Stock Rating Reaffirmed by CitigroupCitigroup restated a "neutral" rating and issued a $59.00 target price (up previously from $48.00) on shares of Mirati Therapeutics in a research note on Wednesday.December 15, 2023 | finance.yahoo.comInsider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)December 12, 2023 | morningstar.comMirati Therapeutics Inc MRTXDecember 12, 2023 | finance.yahoo.comBillionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading ChargesDecember 11, 2023 | marketbeat.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Sold by Braidwell LPBraidwell LP lowered its stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX - Free Report) by 46.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 240,625 shares of the biotechnology company's stocDecember 10, 2023 | marketbeat.comCamber Capital Management LP Buys 400,000 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX)Camber Capital Management LP raised its position in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX - Free Report) by 28.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,800,000 shares of the biotechnolDecember 8, 2023 | marketbeat.comCasdin Capital LLC Reduces Stock Holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX)Casdin Capital LLC reduced its holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX - Free Report) by 95.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,814 shares of the biotechnology company's stock after selling 48December 3, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX), Short Interest ReportDecember 3, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX) Dividends: History, Yield and DatesNovember 15, 2023 | benzinga.comMoore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law FirmNovember 10, 2023 | marketwatch.comMirati Therapeutics Gets CHMP Backing for KrazatiNovember 10, 2023 | reuters.comMirati's lung cancer drug gets EU's regulatory backingNovember 10, 2023 | finance.yahoo.comUPDATE 1-Mirati's lung cancer drug gets EU's regulatory backingNovember 8, 2023 | msn.comLeerink Partners Downgrades Mirati Therapeutics (MRTX)November 8, 2023 | msn.comStifel Downgrades Mirati Therapeutics (MRTX)November 7, 2023 | finance.yahoo.comParamount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cutsNovember 6, 2023 | finance.yahoo.comMirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comMirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 3, 2023 | marketwatch.comMirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer PatientsNovember 2, 2023 | finance.yahoo.comKura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNovember 2, 2023 | msn.comMirati Therapeutics (MRTX) Price Target Increased by 16.97% to 64.71October 26, 2023 | finance.yahoo.comMirati Therapeutics Inc (26M.BE)October 18, 2023 | markets.businessinsider.comHold Rating on Mirati Therapeutics: A Comparative Analysis with Amgen and Future ProspectsOctober 12, 2023 | msn.comPiper Sandler Downgrades Mirati Therapeutics (MRTX)October 11, 2023 | markets.businessinsider.comMirati Therapeutics Falls 5% After Bristol Myers Squibb Decides To Acquire ItOctober 11, 2023 | finance.yahoo.comMirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8BOctober 10, 2023 | msn.comMirati Therapeutics: Anatomy Of A Long Simmering BuyoutOctober 9, 2023 | businesswire.comMIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati ...October 9, 2023 | msn.comMirati Therapeutics could see another bidder emerge, Leerink saysOctober 9, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers SquibbOctober 8, 2023 | businesswire.comMRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to ShareholdersOctober 8, 2023 | marketwatch.comBristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billion Get Mirati Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump. Click here to see why it will be ______ _________. MRTX Media Mentions By Week MRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRTX News Sentiment▼0.000.83▲Average Medical News Sentiment MRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRTX Articles This Week▼03▲MRTX Articles Average Week Get Mirati Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALKS News Today PRGO News Today ALPN News Today NUVL News Today AXSM News Today INSM News Today HCM News Today BHVN News Today RARE News Today PBH News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRTX) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
